Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Debt (2016 - 2025)

Cytokinetics (CYTK) has disclosed Total Debt for 14 consecutive years, with $287.6 million as the latest value for Q4 2025.

  • Quarterly Total Debt changed N/A to $287.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $287.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $287.6 million for FY2025, N/A changed from the prior year.
  • Total Debt for Q4 2025 was $287.6 million at Cytokinetics, up from $176.0 million in the prior quarter.
  • The five-year high for Total Debt was $287.6 million in Q4 2025, with the low at $46.5 million in Q1 2021.
  • Average Total Debt over 5 years is $90.5 million, with a median of $64.1 million recorded in 2023.
  • The sharpest move saw Total Debt fell 4.18% in 2023, then skyrocketed 73.31% in 2024.
  • Over 5 years, Total Debt stood at $47.4 million in 2021, then surged by 36.74% to $64.8 million in 2022, then increased by 5.71% to $68.5 million in 2023, then skyrocketed by 54.12% to $105.5 million in 2024, then surged by 172.53% to $287.6 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $287.6 million, $176.0 million, and $176.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.